UltraGreen.ai's shares dropped 49.6% last week, closing at $0.635 on August 21. This decline followed news of new competitors entering the U.S. market. The company focuses on indocyanine green (ICG) products for fluorescence-guided surgery. It announced plans to adjust its strategy due to pricing and distribution tactics from U.S. rivals Zydus Lifesciences and Provepharm. CEO Ravinder Sajwan said that while competition is not new, recent regulatory approvals for these rivals raised concerns among shareholders.
Key Details
On August 24, UltraGreen.ai's shares briefly rose by 18.1%, reaching $0.75. However, gains were reduced to $0.645 by mid-morning. The company still expects fiscal year 2026 revenue between $175 million and $185 million, despite competitive pressures. Sajwan pointed out that FDA approval does not guarantee commercial success or market penetration. The company also plans to expand beyond ICG products by integrating dye, imaging, and software solutions.
Background
DBS Group Research reacted to these developments by cutting its price target for UltraGreen.ai to $0.80. It also downgraded its recommendation from “buy” to “hold.” The firm provided a range of estimates for the company's 2027 earnings based on different assumptions about sales volume and pricing for ICG products. Sajwan confirmed that there has been no significant change in the company's business outlook that would require a revision of its guidance.
Related coverage: Unitree Robotics Shares Surge 629% in Shanghai IPO Debut, SpaceX Shares Face Pressure as 319 Million Become Saleable.
The sharp decline in UltraGreen.ai's share price shows investor concerns about rising competition in the ICG market. This could lead to lower revenue projections. The stock is expected to remain volatile as investors evaluate the impact of new entrants on market share and pricing strategies. Watch for updates on UltraGreen.ai's competitive strategy and any news about sales performance in the coming quarters.
Based on reporting by: businesstimes.com.sg